Genetic Differentiation, Diversity, and Drug Susceptibility of Candida krusei

Jie Gong¹, Meng Xiao²−³⁷, He Wang⁴⁻⁵, Timothy Kudinha⁶⁻⁷, Yu Wang⁴, Fei Zhao¹, Weiwei Wu⁷, Lihua He¹, Ying-Chun Xu²⁻³⁸ and Jianzhong Zhang¹*  

¹ State Key Laboratory of Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, ² Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, ³ Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Beijing, China, ⁴ School of Biomedical Science, Charles Sturt University, Orange, NSW, Australia, ⁵ Central West Pathology Laboratory, Orange, NSW, Australia, ⁶ Key Laboratory of Wildlife Biotechnology, Conservation and Utilization of Zhejiang Province, Zhejiang Normal University, Jinhua, China, ⁷ Department of Dermatology, Hainan Provincial Center for Skin Disease and STI Control, Haikou, China

Candida krusei is a notable pathogenic fungus that causes invasive candidiasis, mainly due to its natural resistance to fluconazole. However, to date, there is limited research on the genetic population features of C. krusei. We developed a set of microsatellite markers for this organism, with a cumulative discriminatory power of 1,000. Using these microsatellite loci, 48 independent C. krusei strains of clearly known the sources, were analyzed. Furthermore, susceptibility to 9 antifungal agents was determined for each strain, by the Clinical and Laboratory Standards Institute broth microdilution method. Population structure analyses revealed that C. krusei could be separated into two clusters. The cluster with the higher genetic diversity had wider MIC ranges for six antifungal agents. Furthermore, the highest MIC values of the six antifungal agents belonged to the cluster with higher genetic diversity. The higher genetic diversity cluster might have a better adaptive capacity when C. krusei is under selection pressure from antifungal agents, and thus is more likely to develop drug resistance.

Keywords: Candida krusei, invasive candidiasis, genetic differentiation, genetic diversity, microsatellites, drug susceptibility

INTRODUCTION

Invasive candidiasis is the most common fungal disease among hospitalized patients, and affects more than 250,000 people worldwide annually, with more than 50,000 deaths reported (Kullberg and Arendrup, 2015). In the Candida genus, Candida krusei attracts much medical attention because it is intrinsically resistant to fluconazole (Akova et al., 1991; Schuster et al., 2013). In addition, C. krusei exhibits resistance to other antifungal drugs such as voriconazole, echinocandins, and amphotericin B (Fukuoka et al., 2003; Hakki et al., 2006; Pfaller et al., 2008). It has been known for some time that mutations in ERG11 genes are the major mechanisms responsible for azole- and echinocandin-resistance in Candida species, including C. krusei (Jensen et al., 2014; Forastiero et al., 2015; Feng et al., 2016; Perlin et al., 2017). In addition, antifungal resistance can be acquired by over-expression of efflux pump e.g., Abc1p (Lamping et al., 2009; Ricardo et al., 2014). However, there have been some C. krusei antifungal resistant phenotypes, including resistance to azoles other than fluconazole and to echinocandins e.g., caspofungin, that cannot be explained by currently known mechanisms of resistance (Hakki et al., 2006; Whaley et al., 2017).
From an evolutionary perspective, drug resistance in a microorganism is part of the adaptive evolutionary response of a species to environmental pressures (Salmond and Welch, 2008). Nowadays, the environmental pressure of antifungal drugs comes not only from the use of clinical drugs, but also from the use of agricultural drugs (Sanglard, 2016).

The adaptive capacity is usually related to the level of genetic diversity. From the points of molecular ecology, genetic diversity can allow species or populations to adapt quickly to changing environment conditions and different habitats (Freeland et al., 2011). Similarly, from the perspective of conservation genetics, genetic diversity allows species or populations to tolerate a wider range of environmental changes, including bacteria, fungi and so on. Also, genetic diversity is helpful to maintain the evolutionary vigor (Frankham et al., 2010). In general, a higher genetic diversity enables the organism to respond better to new selection pressures (McDonald and Linde, 2002). When there was a selection pressure for exogenous antifungal agents, the more genetic diversity the fungal populations had, the higher the probability of survival. In other words, antifungal agents were the directional selection factors from Darwin’s theory of Evolution. If the genetic diversity of the fungal population was high, there might be some individual death under the pressure of drug selection, but some individuals carrying different genes would survive. Therefore, it is reasonable to hypothesize that microbial populations with higher genetic diversity are more likely to develop antimicrobial drug resistance.

However, to our best knowledge, no research targeting the genetic population features of *C. krusei* has been carried out to date. This is partly due to the lack of a flexible molecular typing method. Therefore, in this study, we (1) developed a novel set of microsatellite markers for molecular typing and population genetic analysis of *C. krusei*; (2) used the developed assay to type 48 multicenter collected *C. krusei* clinical strains; and (3) analyzed the correlation between genetic diversity and drug susceptibility among the studied strains.

**MATERIALS AND METHODS**

**Ethics Statement**

This study was reviewed and approved by the ethics committee of the National Institute for Communicable Disease Control and Prevention, Chinese CDC. Written informed consent was obtained from patients for use of the samples in research.

**Isolate Collection and Identification**

A total of 48 *C. krusei* isolates, each from a single patient, were collected from 15 hospitals distributed in 10 cities across China during the period 2009–2012, as part of the national surveillance program for invasive fungal infections (the...
### TABLE 1 | Characterization of *Candida krusei* microsatellite loci.

| Locus   | Primer sequences (5′–3′)                              | Ta° (C) | Repeat type | Size range (bp) | No. of alleles | PICb | DPc | NCBI accession |
|---------|-------------------------------------------------------|---------|-------------|-----------------|----------------|------|-----|----------------|
| Cakr001 | ACGGACCCCAACACATCAAC GAAAGGAAGGAAGGAAACATCAAC       | 56      | (AT)$_{11}$ | 381–394         | 7              | 0.663| 0.701| MH079517       |
| Cakr002 | GTAGAACCCGTATAGGGGAC GAAAGGAAGGAAGGAAACATCAAC       | 52      | (TA)$_{13}$ | 293–303         | 6              | 0.708| 0.750| MH079518       |
| Cakr003 | CATATCATATGACATTTTCA TCCATCTATTCGGCAACAGG          | 52      | (TCT)$_{11}$| 284–272         | 5              | 0.604| 0.663| MH079519       |
| Cakr004 | AAGGACGGTGCTTTCACTT TTTGACGGTGTCTCGTAGG            | 59      | (TAT)$_{12}$| 365–401         | 11             | 0.739| 0.768| MH079520       |
| Cakr005 | CAGTTCAACTCGGCCTCCTC CAGTTGCTTGCCCTGTCGACC         | 62      | (AAT)$_{17}$| 311–362         | 16             | 0.867| 0.878| MH079521       |
| Cakr006 | TAGTTTGGGAGAATCTGTAT TCACTGTGGACAGGCA             | 56      | (TC)$_{12}$ | 362–370         | 5              | 0.551| 0.621| MH079522       |
| Cakr007 | GTAGGGGGAGGTAAGGAGGT TAACAGCAGGCAAGGAAAGG          | 59      | (CAG)$_{11}$| 174–261         | 8              | 0.803| 0.826| MH079523       |
| Cakr008 | AGCACCCTGAAACTCTCTAC ATCTCAAGCCTTCTAAT             | 52      | (TA)$_{12}$ | 245–257         | 6              | 0.665| 0.716| MH079524       |
| Cakr009 | AGTATCCGAGTCTGTTTA GCTAGGCTCTCTGAGTTTA             | 56      | (AGA)$_{10}$| 223–256         | 9              | 0.561| 0.586| MH079525       |
| Cakr010 | TTGCTGAGTTTGGTCTAAG CATCGTGAGGTCATTTCACT          | 54      | (GAA)$_{10}$| 278–323         | 7              | 0.586| 0.640| MH079526       |
| Cakr011 | AGTGGGAGTTGGGGAAGGAGA TGAACCGGGTCAACAAAGG          | 62      | (CTT)$_{13}$| 357–453         | 13             | 0.822| 0.837| MH079527       |
| Cakr012 | GCAATGTCGGAAATGAACTAG AAAGGACGGAGCAAGGAAAGAAGGA   | 59      | (AT)$_{11}$ | 346–356         | 6              | 0.711| 0.750| MH079528       |
| Cakr013 | TTGTTAAATGTTTGAGGGCC AGATGGGAAAGGCAAGAAGG         | 59      | (AT)$_{10}$ | 246–252         | 4              | 0.335| 0.356| MH079529       |
| Cakr014 | CCAAGGCAATGTCAGGAAAC TTTGAGGACGGCAAAAGG           | 59      | (TG)$_{18}$ | 178–190         | 6              | 0.714| 0.751| MH079530       |
| Cakr015 | CTCTCGCACATTGCGCTATT AACAGGGAATGTTGTAATT          | 54      | (AT)$_{10}$ | 295–305         | 5              | 0.696| 0.742| MH079531       |
| Cakr016 | TAATCAACACATTTGTTCC TTTAGAAGGTTCCTTTCA            | 54      | (AT)$_{10}$ | 193–199         | 4              | 0.313| 0.350| MH079532       |
| Cakr017 | GAAAGAACAGTGGCGGAGGAGC TGCGATGAGCAAGAAGAAGGA      | 59      | (AT)$_{10}$ | 284–314         | 7              | 0.661| 0.703| MH079533       |
| Cakr018 | CATCGGGAGCGTCGTAATA TACAGTGGCAGCTCGCTGTAGG        | 59      | (TA)$_{11}$ | 284–294         | 6              | 0.604| 0.658| MH079534       |
| Cakr019 | CGATTGCTAGCTGGTCTATT ATACCTGAGCTGCCTGTGTTGTTGTTG | 54      | (TCA)$_{11}$| 225–264         | 11             | 0.695| 0.717| MH079535       |
| Cakr020 | TTCCAAACAGCTGCAACTATCCAACATCAGTACCGAAGAAGAAGACGAG | 59      | (AAC)$_{11}$| 275–311         | 9              | 0.735| 0.771| MH079536       |
| Cakr021 | AGCAACAGGAGGGGGACG AGCAACAGGAGGGGGACG            | 56      | (TA)$_{11}$ | 343–365         | 9              | 0.789| 0.814| MH079537       |
| Cakr022 | CGTTTATCATGCCCTCTCTC TAAAGTTGAGCCTCGTAGGG         | 59      | (AT)$_{10}$ | 310–316         | 4              | 0.483| 0.539| MH079538       |
| Cakr023 | GCTAGGGAGGAGGAGGAGC TCTGAGGAGGAGGAGGAGC          | 59      | (TA)$_{11}$ | 267–286         | 9              | 0.638| 0.690| MH079539       |
| Cakr024 | CTTGAGGCCAAGAAGGAGC GATGGATCTGCTCAGG             | 56      | (AAC)$_{10}$| 398–425         | 9              | 0.539| 0.565| MH079540       |
| Cakr025 | AAAAGGGGAAAGAACCAT CAGTTGAGGACCCCTGCAAAAGG      | 54      | (AC)$_{10}$ | 263–321         | 11             | 0.683| 0.728| MH079541       |

(Continued)
### Table 1 Continued

| Locus     | Primer sequences (5′–3′)                                                                                                                                                                                                 | Ta (°C) | Repeat type | Size range (bp) | No. of alleles | PIC          | DP           | NCBI accession |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------------|-----------------|----------------|--------------|--------------|----------------|
| Cakr026   | GGATGTTTTGCGCTCGT GAGGGAGCTGGCCAGAGGA                                                                                                                                                                                  | 59      | (TA)$_{10}$ | 294–314         | 11             | 0.699        | 0.720        | MH079542       |
| Cakr027   | CQAAGTTTGCTGGTCTTAA CATCACAGATCTGCCTTAC                                                                                                                                                                                | 54      | (AT)$_{10}$ | 270–286         | 8              | 0.683        | 0.696        | MH079543       |
| Cakr028   | TTGGAAAGCGAATTAGGTCT AGTCGTCGAAGCAACGAG                                                                                                                                                                                 | 56      | (AT)$_{10}$ | 248–254         | 4              | 0.652        | 0.708        | MH079544       |
| Cakr029   | GTCTAGTCTCGCAATACCT CTTGGTTGGATATAGTTTTC                                                                                                                                                                                | 54      | (CA)$_{10}$(CT)$_{17}$ | 246–286         | 14             | 0.801        | 0.822        | MH079545       |
| Cakr030   | AAACTGCCATCTCAGACG GTACCCTGATGGCGAACAAA                                                                                                                                                                                 | 59      | (CT)$_{11}$ | 147–188         | 8              | 0.557        | 0.581        | MH079546       |
| Cakr031   | CTGTGTGTAATAGCTTTC CTACGAGAAGCTTTGTAAGT                                                                                                                                                                                 | 52      | (CT)$_{10}$ | 347–392         | 10             | 0.636        | 0.659        | MH079547       |
| Cakr032   | TGCTTTTCAAGGCGCTTT GTGGGGATGGGCTTGGTG                                                                                                                                                                                   | 56      | (TC)$_{10}$ | 193–203         | 5              | 0.488        | 0.550        | MH079548       |
| Cakr033   | GGCCTCTGAGTGTACTCATA TCCACAAACTTGAACCTGTC                                                                                                                                                                                | 56      | (CA)$_{11}$ | 265–289         | 6              | 0.701        | 0.739        | MH079549       |
| Mean      | –                                                                                                           | –       | –            | –               | 7.848          | 0.647        | –            | –              |
| Overall   | –                                                                                                           | –       | –            | –               | 1.000          | –            | –            | –              |

*A annealing temperature; *B Polymorphic information content; *C discriminatory power.

CHIF-NET study, Figure 1 and Supplemental A). The isolates were stored at −80°C until use at Peking Union Medical College Hospital, Beijing, China (PUMCH). Before testing, the isolates were inoculated on CHROMagar (l’Etoile, France) as per manufacturer’s instructions, and by sequence analysis of their rDNA internal transcribed spacer (ITS) regions (Wang et al., 2012). The identities of all the isolates was confirmed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS, Vitek MS, bioMérieux, Marcy-l’Etoile, France) as per manufacturer’s instructions, and by sequence analysis of their rDNA internal transcribed spacer (ITS) regions (Wang et al., 2012). The identities of all the isolates was confirmed by sequencing.

### DNA Extraction, Microsatellite Development, and Genotyping

All the fungal isolates were grown on potato dextrose agar at 37°C for 24 h. DNA extraction was performed using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The software SciRoKo was used to identify microsatellites in the C. krusei genome (GenBank assembly accession: GCA_001983325.1, Kofer et al., 2007; Cuomo et al., 2017). Primers were designed using Primer premier 5.0 (PREMIER Biosoft International, Palo Alto, CA, USA) in regions flanking microsatellite loci, and annealing temperatures were optimized with a gradient PCR. Polymorphic microsatellite loci were selected for molecular typing and population genetic analysis of C. krusei. There were two criteria used for selection of microsatellite loci: first, the locus had to have a relatively high genetic polymorphism (the number of alleles was >3); second, the locus could be amplified relatively stable. The microsatellite loci would be abandoned if the loci was not amplified in more than two strains.

For the 33 selected microsatellite loci (Table 1), PCR was performed on 48 clinical isolates. Amplification was carried out using a Taq polymerase kit (Takara, Dalian, China). Each of the amplification reactions was composed of 1 × PCR buffer, 0.2 µM dNTP, 0.5 U Taq polymerase, 0.2 µM each primer, and 2 µl genomic DNA (20–50 ng/µl). The thermocycler conditions were as follows: initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at an optimized primer-specific annealing temperature for 30 s (Table 1), extension at 72°C for 30 s and final extension at 72°C for 10 min. The primers for these selected loci were fluorescently labeled with 6-carboxy-fluorescein (6-FAM). Allele length was determined by migration of PCR products on an ABI 3,700 automated capillary DNA sequencer (Applied Biosystems). Allele sizes were assigned with GeneMapper software (version 3.7) according to an internal size standard (LIZ 500, Applied Biosystems).

### Antifungal Susceptibility Testing

The *in vitro* susceptibility to nine antifungal drugs- fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B, and 5-flucytosine, was determined for 48 isolates using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Minimum inhibitory concentration (MIC) results for fluconazole, voriconazole, caspofungin, micafungin, and anidulafungin, were interpreted using clinical breakpoints in accordance with the CLSI guidelines (CLSI, 2017), and those for itraconazole, posaconazole, amphotericin B, and 5-flucytosine,
were interpreted using epidemiological cut-off values (Xiao et al., 2014). The quality control strains used were C. krusei ATCC 6,258 and Candida parapsilosis ATCC 22,019.

Data Analysis
Deviation from Hardy-Weinberg equilibrium was computed using GENEPPO version 4 (Rousset, 2008). Hardy-Weinberg equilibrium was tested using the score test for heterozygote deficiency and the significance was addressed by a Markov Chain algorithm (Markov chain parameters: dememorization number = 2,000, number of batches = 250, number of iterations per batch = 2,000).

The discriminatory power of markers was calculated according to the method of Hunter and Gaston (1988). Number of alleles (nA), effective number of alleles (ne), Shannon's Information Index (I), and Nei's unbiased gene diversity (HS), were calculated using GENALEX 6.5 (Peakall and Smouse, 2012). Allelic Richness (AR) was calculated by FSTAT 2.9.3 (Goudet, 1995). Ne, I, HS, and AR were used to measure genetic variability of populations.

Population composition was inferred for the C. krusei isolates using the program Structure 2.3 (Pritchard et al., 2000), which estimates the log probability of the data for each value of K (number of clusters or populations). A series of independent runs were performed by using K from 1 to 12 populations, a burn-in of 100,000 Markov chain Monte Carlo (MCMC) iterations, and a data collection period of 100,000 MCMC iterations. Each simulation of K was replicated 10 times. The method of Evanno et al. (2005) was used to estimate the most likely K given the data with Structure Harvester (Earl, 2012). The level of genetic differentiation at microsatellite loci among clusters was estimated as FST, which is simply a measure of how genetically similar populations are to one another. FST was calculated using Arlequin 3.5 (Excoffier and Lischer, 2010). Principal coordinates analysis (PCoA) of FST value among clusters was calculated using GenAlEx (Peakall and Smouse, 2012).

For antifungal susceptibility results, MIC50, MIC90, and geometric mean (GM) MIC values were calculated using WHONET software (version 5.6, WHO Collaborating Center for Surveillance of Antimicrobial Resistance, Boston, USA).

![FIGURE 2](https://example.com/figure2.png) STRUCTURE analyses of 48 C. krusei strains. (A) STRUCTURE analysis estimates that the optimal predicted number of populations K for our set of genotypes is two. (B) Bayesian estimation of the population structure of C. krusei by STRUCTURE. Each vertical bar represents one individual and is partitioned into colored segments that represent the individual's estimated membership fractions in K clusters.
RESULTS

Microsatellite Loci of *C. krusei*

Based on the genome of *C. krusei*, a total of 200 microsatellite loci were identified, and primers were designed (data not shown). Of these microsatellite loci, 33 polymorphic microsatellite loci (Cakr 001–Cakr 033) could be stably amplified in all *C. krusei* isolates (Table 1). The cumulative discriminatory power of the 33 loci was 1.000. If only 8 polymorphic sites with the highest polymorphism were selected (Cakr004, Cakr005, Cakr011, Cakr019, Cakr025, Cakr026, Cakr029, Cakr031), it was found that the cumulative discriminatory power would still be 1.000. This might mean that the molecular typing of strains could be achieved effectively by using only these 8 microsatellite loci. All loci showed significant deviation from Hardy-Weinberg equilibrium \( (P < 0.05) \).

In addition, it must be noted that many isolates were heterozygote (Supplemental A).

Genetic Differentiation and Diversity

When performing STRUCTURE analyses, the clustering level \( K = 2 \) yielded the largest delta-K value (Figure 2A). At \( K = 2 \), individual isolates could be assigned to two clusters (Figure 2B). Cluster A included 17 strains and cluster B 31 strains. There was no clear relationship between cluster patterns and geographical source of the isolates, and between cluster patterns and disease.
clinical manifestations. The $F_{ST}$ between the two clusters was 0.188 ($P < 0.01$). The principal coordinate analysis (PCoA) supported the result of the STRUCTURE analyses (Figure 3), suggesting that the population of *C. krusei* was divided into two lineages. The PCoA also suggested that two lineages would both consist of strains from different geographical origins and clinical manifestations of disease. However, if patients from whom the isolates were obtained is considered, there appears to be some differences between the two clusters. The hosts of Cluster A strains were mainly children younger than 10 years old or aged people older than 50 years old. In contrast, the hosts of Cluster B covered almost all age groups (Figure 4). Furthermore, the specimen types of Cluster B are also more complex than Cluster A (Figure 5).

The genetic diversity of *C. krusei* was assessed by Shannon’s Information Index, Nei’s unbiased gene diversity and allelic richness. These indices are shown in Table 2. Four indices (Mean number of effective alleles, Shannon’s Information Index, Nei’s unbiased gene diversity, allelic richness), all showed that there was a higher genetic diversity in cluster B.

**In vitro Susceptibilities**

All isolates were intrinsically resistant to fluconazole (MICs ≥ 16 mg/L; Figure 6, Supplemental A). Of the other eight antifungal agents tested, all isolates were susceptible or of wild-type phenotype to voriconazole, itraconazole, posaconazole, anidulafungin, micafungin, 5-flucytosine, and amphotericin B. Only two of 48 isolates (4.2%) were interpreted as intermediate to caspofungin, both of which belonged to microsatellite cluster B, while the rest 95.8% (46/48) isolates remained susceptible to caspofungin (Figure 6, Supplemental A).

The Geometric mean (GM) MIC, MIC$_{50}$, and MIC$_{90}$ of the two clusters were generally similar, while the MIC range differed between the two clusters (Table 3, Figure 6). For most antifungal agents (6/9) (including caspofungin, posaconazole, voriconazole, itraconazole, fluconazole, amphotericin B), cluster B had a wider MIC range. It is worth noting that the highest MIC values of all 6 antifungal agents were confined to cluster B.

**DISCUSSION**

The correlation between genetic diversity and adaptive capacity of the population has long been studied in the field of molecular ecology. For example, it was found that the *Arabidopsis thaliana* population with higher genetic diversity had better colonization success (Crawford and Whitney, 2010). In principle, the process of fungal infection and clinical manifestation of disease is also considered a colonization success. Unfortunately, very few studies have been done on fungal infections and drug-resistance from the perspective of population genetics. In this study, we carried out a comprehensive analysis of the population genetic features and drug resistance, and attempted to elucidate the drug resistance of *C. krusei* from an evolutionary perspective.

Although an important pathogenic fungal species, the population genetic parameters of *C. krusei* have remained largely unknown. In this study, a novel array of microsatellite markers was developed for molecular typing and population genetic analysis of the species. The discriminatory index of the new

| Table 2 | Genetic diversity of Candida krusei subgroups. |
|---------|-----------------------------------------------|
| Subgroup | Number of strains | $N_A^a$ | $N_e^b$ | $I^c$ | $H^d$ | AR$^e$ |
|----------|-------------------|---------|---------|-------|-------|-------|
| Cluster A| 17                | 2.545   | 1.865   | 0.645 | 0.416 | 2.527 |
| Cluster B| 31                | 7.667   | 4.186   | 1.583 | 0.737 | 6.659 |
| Total    | 48                | 5.106   | 3.025   | 1.114 | 0.576 | 6.165 |

$^a$Mean number of alleles; $^b$Mean number of effective alleles; $^c$Shannon’s Information Index; $^d$Nei’s unbiased gene diversity; $^e$Allelic richness.
FIGURE 6 | MIC range and proportion of two C. krusei clusters.

TABLE 3 | GM MIC, MIC50, MIC90, and MIC range of C. krusei subgroups.

| Subgroup | Anidulafungin (µg/ml) | Micafungin (µg/ml) | Caspofungin (µg/ml) | 5-Flucytosine (µg/ml) | Fluconazole (µg/ml) | Voriconazole (µg/ml) | Voriconazole (µg/ml) | Itraconazole (µg/ml) |
|----------|-----------------------|--------------------|---------------------|-----------------------|---------------------|---------------------|---------------------|---------------------|
| Cluster A | GM MIC<sup>a</sup> | 0.04 | 0.11 | 0.21 | 12.03 | 0.15 | 0.17 | 0.17 | 32.00 | 0.59 |
|          | MIC<sub>50</sub><sup>b</sup> | 0.06 | 0.12 | 0.25 | 16 | 0.25 | 0.25 | 0.25 | 32 | 0.5 |
|          | MIC<sub>90</sub><sup>c</sup> | 0.06 | 0.12 | 0.25 | 16 | 0.25 | 0.25 | 0.25 | 64 | 1 |
|          | MIC range | 0.015–0.12 | 0.06–0.12 | 0.12–0.25 | 4–16 | 0.03–0.25 | 0.12–0.25 | 0.06–0.25 | 16–64 | 0.25–1 |
| Cluster B | GM MIC | 0.04 | 0.11 | 0.20 | 13.68 | 0.18 | 0.17 | 0.16 | 38.27 | 0.63 |
|          | MIC<sub>50</sub> | 0.03 | 0.12 | 0.25 | 16 | 0.25 | 0.25 | 0.25 | 32 | 0.5 |
|          | MIC<sub>90</sub> | 0.06 | 0.12 | 0.25 | 16 | 0.25 | 0.25 | 0.25 | 64 | 1 |
|          | MIC range | 0.03–0.12 | 0.06–0.12 | 0.12–0.5 | 4–16 | 0.03–0.5 | 0.03–0.5 | 0.06–0.5 | 16–128 | 0.25–2 |
| Overall  | GM MIC | 0.04 | 0.11 | 0.20 | 13.07 | 0.17 | 0.17 | 0.16 | 35.92 | 0.61 |
|          | MIC<sub>50</sub> | 0.03 | 0.12 | 0.25 | 16 | 0.25 | 0.12 | 0.25 | 32 | 0.5 |
|          | MIC<sub>90</sub> | 0.06 | 0.12 | 0.25 | 16 | 0.25 | 0.25 | 0.25 | 64 | 1 |
|          | MIC range | 0.015–0.12 | 0.06–0.12 | 0.12–0.5 | 4–16 | 0.03–0.5 | 0.03–0.5 | 0.06–0.5 | 16–128 | 0.25–2 |

<sup>a</sup>Geometric mean Minimum inhibitory concentration; <sup>b</sup>Mean minimal inhibitory concentrations against 50 percent of strains; <sup>c</sup>Mean minimal inhibitory concentrations against 90 percent of strains.

method (1.000) was slightly higher than MLST, which exhibited a discriminatory index of 0.998 (Jacobsen et al., 2007). It has been shown by Cuomo et al. (2017) that the genome of C. krusei is highly heterozygous, and this was also confirmed in the present study. For all microsatellite loci, there were some heterozygous individual isolates. As previously described in Candida albicans, a significant departure from Hardy-Weinberg equilibrium expectations was found (Sampaio et al., 2003). This finding supports the previous conclusions that reproduction in C. krusei is mainly clonal.

Based on the STRUCTURE software analysis, the C. krusei population in China appears to be divided into two clusters, a result which was also supported by PCoA. The two clusters showed no obvious differences with respect to geographical distribution of the isolates. These findings are very similar to those of another pathogenic fungus, Trichophyton rubrum, which was also divided into two clusters with similar geographical distributions of the clusters (Gong et al., 2016). For pathogenic fungi, it might be a common phenomenon that different clusters of the same organism co-exist in the same geographical locale. Dispersal of pathogenic fungi is generally affected by host activity. It is highly possible that C. krusei strains of different clusters existed in different geographical areas and were carried to the same geographical area by hosts including humans. When the...
survival capacity of different clusters is similar, it indicates that the different clusters co-existed in the same area. However, there were significant differences in host age between the two clusters, which might suggest that cluster B strains have a higher pathogenicity. Moreover, the type of specimens in Cluster B were also more complicated and seemed to confirm this. However, this is only a hypothesis, and more work needs to be done to demonstrate these findings in animal infection model experiments.

Cluster B had a higher genetic diversity which suggests a better adaptive capacity for survival in challenging conditions. As previously mentioned, the population with a higher genetic diversity is more likely to develop antimicrobial drug resistance. In our study, cluster B had a wider MIC range for 6 antifungal drugs, although there was no obvious difference in GM MIC, MIC50, and MIC90 between the two clusters. Specifically, the strains with the highest MIC value were either in the current group B (including 6 drugs: caspofungin, posaconazole, voriconazole, itraconazole, fluconazole, and amphotericin B), or both in group A and group B (including 3 drugs: anidulafungin, micafungin, and 5-flucytosine). Meanwhile, there was no strain with the highest MIC value was observed in Cluster A. These findings suggest that the population with higher genetic diversity may have more diverse phenotypes, including drug resistance. When subjected to selective pressure from antifungal drugs, cluster B might have a better adaptive capacity, and thus would be more likely to develop drug resistance. This suggests that the C. krusei population or lineage with higher genetic diversity needs more attention in terms of fungal drug resistance.

In conclusion, C. krusei was divided into two clusters by novel high-resolution microsatellite markers. The cluster with higher genetic diversity had wider MIC ranges for six antifungal agents, and the highest MIC values of the six antifungal agents belonged to the cluster of higher genetic diversity. It is plausible that the C. krusei cluster with higher genetic diversity might have better adaptive capacity when under the selection pressure of antifungal agents.

**AUTHOR CONTRIBUTIONS**

JZ and Y-CX designed the experiments. JG, MX, HW, FZ, LH, and WW collected the samples and performed the experiments. JG, MX, TK, and YW analyzed data. JG, MX, and TK wrote the manuscript. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

This work was supported by a Peking Union Medical College Hospital Out-standing Young Talents Program (JQ201703), a Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-I2M-1-014), a Beijing Innovation Base Cultivation and Development Special Fund (Z171000002217068), and the Major Infectious Diseases Such as AIDS and Viral Hepatitis Prevention and Control Technology Major Projects (2018ZX10171001).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fmicb.2018.02717/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fmicb.2018.02717/full#supplementary-material)
Jensen, R. H., Justesen, U. S., Rewes, A., Perlin, D. S., and Arendrup, M. C. (2014). Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei. Antimicrob. Agents Ch. 58, 3550–3552. doi: 10.1128/AAC.02367-14

Koller, R., Schlötterer, C., and Lelley, T. (2007). SciRoKo: a new tool for whole genome microsatellite search and investigation. Bioinformatics 23, 1683–1685. doi: 10.1093/bioinformatics/btm157

Kullberg, B. J., and Arendrup, M. C. (2015). Invasive candidiasis. N. Engl. J. Med. 373, 1445–1456. doi: 10.1056/NEJMra1315399

Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D., Niimi, K., Holmes, A. R., et al. (2009). Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob. Agents Chemother. 53, 354–369. doi: 10.1128/AAC.01093-08

McDonald, B. A., and Linde, C. (2002). Pathogen population genetics, evolutionary potential, and durable resistance. Annu. Rev. Phytopathol. 40, 349–379. doi: 10.1146/annurev.phyto.40.120501.101443

Peakall, R., and Smouse, P. (2012). GenAlEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research: an update. Bioinformatics 28, 2537–2539. doi: 10.1093/bioinformatics/bts460

Perlin, D. S., Rautemaa-Richardson, R., and Alastraue-Izquierdo, A. (2017). The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect. Dis. 17, e383–e392. doi: 10.1016/S1473-3099(17)30316-X

Pfäffler, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., et al. (2008). Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the artemis disk antifungal surveillance program, 2001 to 2005. J. Clin. Microbiol. 46, 515–521. doi: 10.1128/JCM.01915-07

Pritchard, J. K., Stephens, M., and Donnelly, P. (2000). Inference of population structure using multilocus genotype data. Genetics 155, 945–959.

Ricardo, E., Miranda, I. M., Faria-Ramos, I., Silva, R. M., Rodrigues, A. G., and Pina-Vaz, C. (2014). In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. Antimicrob. Agents Chemother. 58, 4604–4611. doi: 10.1128/AAC.02603-14

Rousett, F. (2008). Genepop’007: a complete re-implementation of the genepop software for Windows and Linux. Mol. Ecol. Resour. 8, 103–106. doi: 10.1111/j.1471-8286.2007.01931.x

Salmond, G. P., and Welch, M. (2008). Antibiotic resistance: adaptive evolution. Lancet 372, S97–S103. doi: 10.1016/S0140-6736(08)61888-7

Sampaio, P., Gusmão, L., Alves, C., Pina-Vaz, C., Amorim, A., and Pais, C. (2003). Highly polymorphic microsatellite for identification of Candida albicans strains. J. Clin. Microbiol. 41, 552–557. doi: 10.1128/JCM.41.2.552-55.7.2003

Sanglard, D. (2016). Emerging threats in antifungal-resistant fungal pathogens. Front. Med. 3:11. doi:10.3389/fmed.2016.00011

Schuster, M. G., Meibohm, A., Lloyd, L., and Strom, B. (2013). Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. J. Infection. 66, 278–284. doi: 10.1016/j.jinf.2012.11.002

Vega, P., Alberdi, A., Castano, L., Marques, J. G., and Sánchez, A. (2016). New insights into the Candida krusei genome. Bioinformatics 32, 715–724. doi: 10.1093/bioinformatics/btv689

Wang, H., Xiao, M., Chen, S. C., Kong, F., Sun, Z. Y., Liao, K., et al. (2012). In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 national china hospital invasive fungal surveillance net (CHIF-NET) study. J. Clin. Microbiol. 50, 3952–3959. doi: 10.1128/JCM.01139-12

Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., and Rogers, P. D. (2017). Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front. Microbiol. 7:2173. doi: 10.3389/fmicb.2016.02173

Xiao, M., Fan, X., Chen, S. C., Wang, H., Sun, Z. Y., Liao, K., et al. (2014). Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J. Antimicrob. Chemother. 70, 802–810. doi: 10.1093/jac/dku360

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Gong, Xiao, Wang, Kudinha, Wang, Zhao, Wu, He, Xu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.